The 1 analysts offering 12-month price forecasts for Nabriva Therapeutics PLC have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 2.00. The median estimate represents a +954.30% increase from the last price of 0.19.
The current consensus among 2 polled investment analysts is to Buy stock in Nabriva Therapeutics PLC. This rating has held steady since January, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.19
Reporting Date Aug 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.